India: Biotechnology And Allied Sciences Patent Provisions In India

The biotechnological inventions majorly include products and/or processes of gene engineering technologies, methods of isolation of micro-organisms from culture medium, methods of mutation, cultures, mutants, transformants, plasmids, processes for making monoclonal antibodies, etc.1 Often, the focus is laid on controversial issues surrounding biotechnology patenting such as criteria for patenting plants and animals, the patenting of gene sequences and related morality issues. Contrary to the aforesaid issues, majority of biotechnology patent applications are decided on serious issues of patent system such as novelty, inventive step and industrial application as well as the sufficiency of disclosure and support of the description to the claims.

Biotech inventions are considered in the same light as the other inventions. The Patents Act, 1970, seeks to help the applicants as well as the examiners of patents as it covers not only at how the basic issues of protecting biotechnological inventions have been applied in the past but also at how they should be applied, subject to guidance from courts and the Intellectual Property Appellate Board (IPAB) in the context of recent developments in the technology. This article endeavors to throw light of such aspects and explicitly discusses the provisions with regard to patenting of biotechnological inventions.

Prior Art Search

The draft guidelines issued by the Indian Patent Office on 25th March 2013 mandates the examiner to design a comprehensive search strategy by combining various search parameters including key words, IPC, sequences etc., and thorough search should be carried out in patent as well as non-patent literature. If a patent application consists a sequence listing of nucleotides or amino acids then Rule 9 (1) of the Patents Rule (2003), specifies that the same is to be filed by the applicant in electronic form2. A thorough search of the sequence has to be carried out by the examiner on the commercial databases available to the office using BLAST, FASTA, etc.


It is mandated that novelty has to be assessed in the same manner as that for other inventions. Novelty has to be interpreted vis-à-vis prior art as provided under Section 13 of the Act. To ascertain novelty as per Sec 2(1)(j) of the Act, the following different kinds of claims can be evaluated namely,

  1. Product-by-process claims: A claim describing a product should not be anticipated by a prior disclosure of that particular product per se regardless of the method of production of the product. The claimed product cannot be considered as novel, if the process by which it is produced is novel. In order to establish novelty, technical evidences are required to show that the modifications in the processes result in other products which are distinct with regard to their properties over the products known in the prior art.
  2. Sequence claims: If any applicant claims that a polynucleotide sequence which was already available in a library is not novel, even if the function of that particular sequence was not previously characterized. If any sequence of a polynucleotide from a prior art doesn't match exactly to the claimed sequence of polynucleotide, then the subject matter is considered novel. The same applies to a polypeptide sequence.
  3. Combination/Composition claims: The claims of combination of products of biotechnology are often missed out while assessing novelty instead is dealt under the inventive step or other relevant clauses of Section 3 of the Act. However, since combination/ composition claims have already fallen into the public domain, they have to be dealt under novelty.

Inventive step

According to the Patents Act, 1970, an invention will have inventive step if it is technically advanced or economically advanced when compared to the existing knowledge and it should be non-obvious to a person with ordinary skilled in that art. Example, structurally and functionally similar polynucleotide/polypeptide sequences are considered to be obvious. Similarly claim for a sequence with minor variations/mutations in the amino acid sequences which do not alter the activity and function of a protein sequence which is already in public domain cannot be patented due to the lack of inventive step. Therefore, the applicant should provide evidences to highlight the difference between the encoded protein disclosed in the prior art and that encoded by the claimed DNA for which a patent is being sought.

Industrial Application

As per Section 2(1) (ac) of the Act, "Capable of industrial application" in relation to an invention, means that the invention is capable of being made or used in an industry. Mere discovering a gene sequence and the protein encoded by it doesn't ensure patent protection unless a distinct and credible use of the gene sequence is specified. To establish industrial applicability of a gene sequence, the use of the sequence and the significance of the product encoded by it has to be stated. Section 64(1) (g) of the Act provides that if the invention do not meet the criteria of industrial applicability, it is deemed to be revoked.

Fragments /Expressed Sequence Tags (ESTs)

Fragments/ESTs are allowable only if they satisfy the question of usefulness and industrial application. A credible and substantial use of the EST should be disclosed. For Example, use of ESTs as a probe or chromosome marker to diagnose a specific disease condition.

It is mandated that adequate care has to be taken while examining inventions whose commercial exploitation is speculated to be contrary to public order, morality or causes serious prejudice to human, animal or plant life or to the environment as per the provisions mentioned in Section 3(b) of the Act. (e.g., cloning of mammals, modifications in the germ line and genetic identity of living organisms, terminator gene technology and use of human embryos)

As per Section 3(c) of the Act, the products such as microorganisms, nucleic acid sequences, proteins, enzymes, compounds, etc., which are directly isolated from nature are not patentable subject matter. However, the exception to this provision is the processes of isolation of these products can be considered subject to requirements of Section 2(1) (j) of the Act.

Section 3(d) of the Act provides that any minor modifications in the already existing substance in the prior art are not patentable unless the improved property or efficacy of the modified substance is established. With respect to biotechnology patent applications, section 3(d) is applicable to those inventions relating to a three-dimensional or crystal structure of a polypeptide unless it is proved that such polypeptide differs significantly in properties with regards to therapeutic efficacy.

Further, Section 3(e) establishes that a composition comprising a combination of substances naturally occurring in nature is not patentable subject matter unless the synergistic effect of the components is established. In the light of chemical and biotechnological sciences, Section 3(e) of the Act reflects the legislative intent on the law of patenting of combination inventions.

According to Section 3(h) of the Act, a method of agriculture (a method of spraying insecticide for controlling pests) or horticulture is not considered as patentable subject matter. Conventional methods performed on actual open fields should be construed as method of agriculture/horticulture.

Section 3(i) of the Act emphasizes that any method of treatment including diagnostic procedures or method of drug administration either to humans or animals are not patentable. Some inventors draft composition of drugs in certain dosage forms and claims that subject matter relates to application or administration of individual drugs. In such cases, although the claims are directed to a combination of drugs, but the claimed invention resides in the method of administration of individual drugs in the said manner and thus, it falls within the scope of Section 3 (i) of the Act. Patenting on gene based diagnostics is completely ruled out.

As per Section 3(c) of the Act, it is mandated that microorganisms are not patentable. It is implied also that only modified microorganisms are patentable subject matter under the Act. Claims relating to basic biological processes of growing plants, germination of seeds, of development stages of plants and animals are not patentable. In relation to biotechnological inventions, bio-informatics is relatively a new science that has evolved from the combination of information technology and biotechnology. Determination of patentability of inventions pertaining to bio-informatics is examined vis-à-vis the provisions mentioned under section 3(k) of the Act.

Section 10(4) of the Act requires that every complete specification shall fully and particularly describe the invention and its operation or its use and by the method by which it is to be performed. In case of biotechnological inventions, it is possible that the gene may play a vital role in the treatment of one or more of the listed diseases. But it is very unlikely that the gene or the protein it produces will have a role in all of the diseases. Such claims are made when the function of the protein is not fully characterized. Therefore the potential uses of the protein claimed are speculative. It is hence evident that if there is no evidence in the complete specification as filed that the gene/ polypeptide is of therapeutic or diagnostic use in the laundry list of different diseases listed, then the specification is insufficient.

Claims to antibodies that may have therapeutic or diagnostic potential are not valid if a role for the target protein in a specific disease has not been identified and proved by sufficient data.

Section 10(5) of the Act, provides that the claim(s) shall be clear and succinct and shall be fairly based on the matter disclosed in the specification. Also, the claim(s) of a complete specification shall relate to a single invention, or to a group of inventions linked so as to form a single inventive concept. In case of genetic engineering patent applications, it is very frequently observed that an application claim a large number of polynucleotide/polypeptide sequences. Lack of unity create problem during publication, examination and searching stage. Further, it is unclear whether the claimed sequence relates to a single invention or to a group of inventions linked so as to form a single inventive concept.

Deposit of biological material

The draft guidelines mandate that the biological material which cannot be described in a sufficient manner and which is not available to the public has to be deposited to an International Depository Authority (IDA) under the Budapest Treaty. The deposit is to be made before filing of the patent and a reference of the deposit is to be submitted within three months from the date of filing of the patent application in India. It is necessary for the inventory to correctly identify and indicate the characteristics which are to be included in the specifications and it should also include name, address of the depository institute and the date and number of the deposit. In India, Microbial Type Culture Collection (MTCC), Chandigarh is the International Deposit Authority (IDA).

The Biodiversity Act , 2002

The BD Act came into force on 1st July 2004.The BD Act provides a mechanism to prevent the misappropriation of biological resources and traditional knowledge by introducing provisions for mandatory prior permission from the National Biodiversity Authority by the applicant for any patent application based on research or any information related to biological resources obtained from India.

According to this Act, the applicant has to provide a mandatory disclosure of the source and geographical origin of the biological material in the patent application. An applicant has also to provide a declaration in Form 1 of the Patent Rules, 2003 about the permission from the competent authority.


In addition to the basic patenting issues, special issues such as moral and ethical concerns, cloning of farm animals, stem cells, gene therapy, patenting of DNA and ESTs of gene sequences, etc., have also evolved. Therefore, setting norms and protocols for assessing biotechnological inventions poses challenges to the applicants for patents as well as to the Patent Office. In view of the aforesaid, the biotechnology and allied sciences patent provisions in India serves as a potential guide in order to establish uniform and consistent practice with regard to the patent applications made in the said technologies.


1 Guidelines For Examination of Biotechnology Applications For Patent, Office of The Controller General of Patents, Designs and Trade Marks, March 2013; available from, (Last accessed on 03th June, 2013)

2 Manual of Patent Office Practice and Procedure, Office of The Controller General of Patents, Designs and Trade Marks, March 2011, available from (Last accessed on 3th June,2013)

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Vaish Associates Advocates
Vaish Associates Advocates
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Vaish Associates Advocates
Vaish Associates Advocates
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions